BACKGROUND: Treatment for early-invasive adenocarcinoma of the cervix remains controversial. Although data have shown similar survival rates to those seen with squamous cell carcinoma, conservative options for patients with microinvasive adenocarcinoma have not been as widely accepted. Despite comparable survival outcomes, patients with earlyinvasive adenocarcinoma are still routinely subjected to more radical surgical techniques than their equivalently staged squamous cell counterparts. OBJECTIVE: The objective of the study was to evaluate how less radical surgery has an impact on 5 year survival in patients with microinvasive adenocarcinoma of the cervix. 
There was no statistical difference in survival between patients having either cell type undergoing local excision (P ¼ .26), simple hysterectomy (P ¼ .08), or radical hysterectomy (P ¼ .87). We also found no statistically significant difference in survival among patients with adenocarcinoma compared by treatment type (local excision compared with simple hysterectomy [P ¼ .64]; local excision compared with radical hysterectomy [P ¼ .82]; or simple hysterectomy compared with radical hysterectomy [P ¼ .70]). Among patients with adenocarcinoma, 0.97% had positive pelvic lymph nodes, none had positive aortic lymph nodes, and 91.85% had confirmed negative lymph nodes. For squamous cell carcinoma, 0.72% of patients had positive pelvic lymph nodes and 0.10% had positive aortic lymph nodes. CONCLUSION: There was no significant difference in survival when patients were compared by cell type or procedure, suggesting that survival of patients with microinvasive adenocarcinoma is not improved by utilizing more invasive surgical methods. Regardless of histology, the frequency of nodal involvement was very low among both groups, supporting an overall excellent prognosis for all patients with microinvasive disease. We submit these data as evidence that preoperative planning of more conservative techniques is appropriate, not just for those with squamous histology or who desire future fertility, but for all patients with microinvasive cervical disease.
Key words: adenocarcinoma, cervical cancer, cervix, lymphadenectomy, lymph node dissection, microinvasive, squamous cell carcinoma, survival T he American Cancer Society estimates more that 12,820 new cases of invasive cervical cancer will be diagnosed in the United States in 2017. 1 Despite improved screening and human papillomavirus immunization, approximately 4200 women in the United States still die from this disease each year. 1, 2 Although squamous cell carcinoma (SCC) remains the most common type of cervical cancer, there is evidence that the number of patients diagnosed with adenocarcinoma (ACA) is on the rise. 3 Currently ACA accounts for 20e25% of total cervical cancer cases and 12% of all microinvasive lesions. 3, 4 Various definitions have been used to describe microinvasive carcinoma of the cervix, but the most commonly accepted are from the International Federation of Gynecology and Obstetrics (FIGO) and the Society of Gynecologic Oncologists, neither of which specifies a cell type. The Society of Gynecologic Oncologists defined microinvasive cancer in 1974 as any lesion in which neoplastic cells invade the stroma to a depth of 3 mm below the base of the epithelium, without lymphatic or blood vessel involvement.
The current FIGO definition differentiates microinvasive cancer as one that is identified only microscopically, as opposed to grossly, with a maximum stromal invasion of 5.0 mm in depth and 7.0 mm in width (stage IA). 5 FIGO further subdivides microinvasive cancer into stages IA1 (depth 3.0 mm, width 7.0 mm) and IA2 (depth >3.0 but 5.0 mm, width 7.0 mm). 5 The management for microinvasive SCC has been widely accepted to include conservative therapy by cold-knife cone or extrafascial hysterectomy. 6 In contrast, conservative management for early invasive ACA remains controversial. There has been a long debate regarding the optimal management of these patients because of conflicting study data and suggestions that conservative surgery could lead to persistent or recurrent disease because of difficulty assessing the depth of invasion or the presence of skip lesions.
Investigation into these uncertainties has been difficult in the past because of small patient populations and limited [7] [8] [9] and clearly support cervical conization as an effective management strategy in patients with ACA desiring future fertility. 2, 10 In an effort to overcome these earlier limitations, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to access a larger patient cohort than previously studied. This allowed us to adequately power our study to evaluate the role of conservative surgery, specifically local excision and simple hysterectomy, in patients with earlyinvasive ACA of the cervix.
Our overall objective was to better evaluate the proposal that nonradical surgery can be an appropriate alternative for all patients diagnosed with microinvasive disease (FIGO stage IA1), regardless of cell type. We hope providing this view of patient survival following treatment will improve the ability of clinicians to make evidencebased treatment recommendations for patients in the preoperative setting.
Materials and Methods
The SEER Program of the National Cancer Institute collects and publishes cancer incidence and survival data on the general population through standard population data files derived from the US Census. The information is collected from 18 individual population-based registries throughout the United States and covers approximately 28% of the total US population.
11 Mortality data are provided by death certificates obtained from the National Center for Health Statistics (National Cancer Institute, 2012). The population covered by SEER is comparable with the US general population with regard to poverty and education and includes 26% of African Americans, 38% of Hispanics, 44% of American Indians and Alaska Natives, 50% of Asians, and 67% of Hawaiian/ Pacific Islanders.
11
Because tumors invading up to 5 mm in depth can be associated with varying degrees of horizontal spread, we chose to use FIGO's bidimensional definition of microinvasion, which takes into account both the width and depth of tumor invasion. Therefore, the term microinvasion in this study was equivalent to FIGO stage IA disease. 5 It is important to note, however, that FIGO staging does not provide any stratification regarding lymph vascular space invasion (LVSI), a prognostic factor that should be considered separately for all patients, regardless of histology.
A 2-tailed power calculation was completed using a 95% level of confidence and a equal to 0.05 to determine a total sample size of 2767 patients (1751 squamous, 1016 adenocarcinoma) was required to detect a 2% difference in the 5 year survival with 80% power.
Data for our study were accessed and analyzed using SEER*Stat, version 8.1.2, which utilizes standard populations for the calculation of age-adjusted statistics. 12 To develop our specific sample population, we queried the 18 To stratify patients by surgical procedure, we created a user-defined variable having 4 distinct categories: (1) all patients, (2) local excision, (3) simple hysterectomy, and (4) radical hysterectomy. 13 Any patients receiving adjuvant radiation therapy were excluded from survival analyses, as were patients with concurrent or previous malignancies.
To calculate the survival by procedure type (local excision [LE] vs simple hysterectomy [SH] vs radical hysterectomy [RH] ) and cell type (SCC vs ACA), the relative cumulative survival at 5 years was determined using the Kaplan-Meier method. To assess statistical significance, 95% confidence intervals were calculated and P values were determined using the Fisher exact test. A secondary analysis was then performed, utilizing SEER*Stat to determine the overall frequency of lymph node metastasis in all patients with microinvasive disease (ie, both radiated and nonradiated patients were included in this analysis). To do this, we created a second user-defined variable having 4 distinct subdivisions: (1) all patients, (2) patients with negative lymph nodes, (3) patients with positive lymph nodes, and (4) patients with no lymphadenectomy performed. 14 Once the prevalence of lymph node metastases was determined, we further stratified patients based on the location of positive lymph nodes by performing a second frequency query using a third user-defined variable divided into the following categories: (1) no positive lymph nodes, (2) positive pelvic lymph nodes (further stratified by number of positive nodes, up to 5 total), (3) positive aortic lymph nodes, (4) other distant positive lymph nodes, (5) positive lymph nodes not otherwise specified, and (6) lymph node status not specified. In these queries we did not exclude patients who received radiation therapy because those patients are more often the ones who have positive lymph nodes and excluding them could have led to falsely lowered results.
Results
From 1988 to 2010, there were 54,249 evaluable cases of invasive cervical cancer recorded in the 18 registries of SEER. Of these, 76.37% were diagnosed with squamous cell carcinoma and 23.15% with adenocarcinoma, consistent with previous reports in the literature. 2 After selecting patients with SCC or ACA having only stage IA1 or IA2 disease, there were 6775 total patients with SCC and 1900 total patients with ACA.
After excluding patients who had insufficient survival data, a history of previous or concurrent malignancy, and patients receiving any form of adjuvant radiation therapy (SCC, 10.14%; ACA, 12.05%), the final study population for the primary analysis consisted of 5749 patients with SCC and 1567 with ACA. For survival comparisons, study cohorts were For the secondary analysis investigating lymph node status, there were 1239 patients found with ACA and 6240 patients with SCC having stage IA1 or IA2 disease who underwent lymphadenectomy. Among the patients with ACA, 0.97% had pelvic lymph node metastases, no patients had aortic lymph node metastases, and 91.85% had confirmed negative lymph nodes. In 7.18% of patients, lymph node status was not specified (Table 2 ). Among patients with SCC, the frequency of positive nodal involvement was 0.72% for pelvic lymph nodes and 0.10% for aortic lymph nodes. In 83.08% of patients, all lymph nodes were negative, and in 16.11% of the patients, no lymph node status was specified (Table 2) .
With regard to current patterns of care, we found that patients with ACA of the cervix are 0.75 times less likely to undergo local excision and 0.61 times less likely to undergo simple hysterectomy than patients with equivalently staged SCC. Patients with ACA are also 2.82 times more likely to undergo a radical hysterectomy compared with patients with equivalent-stage SCC ( Figure 1 ).
As illustrated in Figure 2 , overall 5 year survival was similar among the 2 cell types. We also found no significant difference in survival between the cell types when compared by surgical procedure. All P values confirming nonsignificance are available in Table 1 .
Comment
Currently no consensus exists regarding optimal management of patients with early-stage adenocarcinoma of the cervix. Although a number of previous studies have suggested excellent overall survival for these women, 7,10,15 radical hysterectomy often remains the treatment of choice ( Figure 1) .
Two previous studies have utilized SEER to investigate these outcomes in early adenocarcinoma of the cervix. 7, 10 The first supported extrafascial hysterectomy as appropriate management for women with stage IAI or IA2 ACA based on lymph node status and survival rates but unfortunately was underpowered with only 301 women included from 1988 to 1997. 7 In 2011, the second study compared survival and demographic data for patients having stage IA1 and IA2 squamous cell carcinoma or adenocarcinoma. Similar survival was seen with both cell types, and the authors concluded that cervical conization appeared to be adequate fertilityconserving therapy for either group. 10 Interpretation of the results from the previously mentioned studies is limited, however, because of smaller patient populations and the inability of SEER to exclude patients who received adjuvant radiotherapy from queries at the time of their investigations. Because it is well established that salvage radiotherapy can have an impact on survival in patients with cervical cancer, [16] [17] [18] disregarding this therapy would obscure any potential impact it has on reported outcomes.
SEER now affords us the ability to exclude these patients receiving adjuvant therapy, thereby eliminating this potential confounder from the survival analyses. The additional registries added to the SEER database since these publications, as well as a prolonged follow-up time, have also helped to increase the power and significance of our study, which utilizes the largest sample population reported to date.
Although ideal data regarding conservative treatment in low-risk or earlystage cervical cancer would be obtained from multicenter randomized controlled trials, accrual has been difficult because of such a restricted patient population.
Currently there are 3 ongoing prospective trials attempting to answer this question. The first is a randomized Gynecologic Cancer Intergroup trial called the Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early-Stage Cervical Cancer (SHAPE) trial, comparing radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. 19 This will include patients with squamous or adenocarcinoma stage IA2 or IB1 disease with <10 mm stromal invasion on biopsy or <50% stromal invasion on pelvic magnetic resonance imaging. Patients with LVSI will be permitted. The total anticipated accrual is 700 patients.
The second is the Conservative Surgery for Women with Cervical Cancer (ConCerv) trial, a multicenter international trial led by the University of Texas M. D. Anderson Cancer Center (Houston, TX), which compares cervical conization and pelvic lymph node dissection to simple hysterectomy and pelvic lymph node dissection. 20 This will include patients with squamous cell (all grades) or adenocarcinoma (grades 1 or 2) stage IA2 or IB1 disease, with a tumor size of 2 cm. Patients with high-risk histology or LVSI will be excluded. The expected accrual is 100 patients.
The third prospective trial is the Gynecologic Oncology Group protocol 278, a multiinstitutional trial investigating simple hysterectomy with pelvic lymphadenectomy vs cone biopsy with pelvic lymphadenectomy for stage IA1 (LVSI or greater), IA2 and IB1 (2 cm) cervical cancer. 21 Patients will be stratified based on fertility preferences and must have squamous, adeno-, or adenosquamous carcinoma and invasion no greater than 10 mm. The primary objective is to examine changes before and after nonradical surgery in bladder, bowel, and sexual function and to determine the incidence and severity of lymphedema after nonradical surgery. The minimum sample size is estimated at 200 patients, but interim analyses and feasibility assessments may require accrual of up to 600.
With respect to lymph node metastasis, previous reports have demonstrated a <1% rate of lymph node metastasis for stage IA1 disease and a 3e6% rate for IA2 disease. 15 Our data show an even lower frequency of nodal involvement among all cohorts (in both SCC and ACA groups). This low rate of It is important to note, however, that the presence of LVSI is an important indicator of prognosis that should be considered when determining whether to perform a lymph node dissection and that further studies are necessary to fully determine the necessity of lymphadenectomy in these patients. 22, 23 Two recent studies have evaluated sentinel lymph node (SLN) dissection in early-stage cervical cancer as a less invasive means of lymph node evaluation. The Ganglion Sentinelle dans le Cancer du Col (SENTICOL) study evaluated 139 patients with FIGO stage IA1 cervical carcinoma and LVSI to stage IB1 using technetium 99 lymphoscintigraphy and patent blue injection followed by laparoscopic lymph node mapping, SLN removal, and lymph node dissection. They found high rates of SLN detection, sensitivity of 92% and 98.2% negative predictive value for metastasis detection. There was at least 1 SLN detected in 136 patients (97.8%). 24 A second study by Salvo et al 25 retrospectively reviewed 188 women with early-stage cervical cancer (stages IA1-IB1) who underwent SLN mapping followed by complete pelvic lymphadenectomy as part of initial surgical management from August 1997 through October 2015. Lymphatic mapping was performed using blue dye, technetium-99, and/or indocyanine green. At least 1 SLN was identified in 170 patients (90%), and bilateral SLNs were identified in 117 patients (62%). There was no difference in detection rates between mapping agents or surgical approach, and only 1 patient had a false-negative result. The study showed a sensitivity of 96.4% and negative predictive value of 99.3%. 25 We acknowledge that there are still limitations to utilizing SEER registry data, the most important of which is the absence of potentially meaningful variables not yet populated in the database (eg, LVSI). This could be important because factors such as a higher tumor grade or LVSI can be associated with an increased risk of more advanced disease or lymph node metastasis.
Because the data in the registries are collected from multiple regions, there is also no central pathology review. This could affect staging for microinvasive disease and possibly lead to inconsistencies in diagnosis, given the geometric complexity of endocervical glands. 26 By utilizing a definition that took into account both depth and width of invasion, we hoped to diminish some of these inconsistencies.
Although our study is limited by its retrospective nature, our findings suggest that choice of surgical approach (LE vs RH vs SH) should not be influenced by cell type and that exposing patients with microinvasive ACA to more extensive surgical dissection may increase potential harm without providing additional benefit. Reducing the radicality of surgery performed in appropriately selected patients should not only decrease perioperative complications and long-term morbidity but also ultimately result in reduced health care costs and improved quality of life.
Surgical and postoperative adjuvant therapy should be more precisely tailored to the risk of failure in these patients. In the face of accurate pathological assessment, we submit patients with microinvasive ACA can be prospectively counseled on conservative management options such as cold-knife cone biopsy or simple hysterectomy in the setting of early-invasive disease without LVSI. Although further studies are necessary to clarify the role of LVSI in these patients, these findings support an overall excellent prognosis for patients with microinvasive cervical carcinoma, regardless of histology.
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